• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Better For You Wellness Appoints Montel Williams, Leslie Bumgarner, Joseph Watson, David Deming, and Dr. Nicola Finley, MD to its Board of Directors

    9/2/21 9:29:00 AM ET
    $HSDT
    $SRNE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $HSDT alert in real time by email

    Columbus, Ohio, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Better For You Wellness, Inc., formerly known as Fast Track Solutions, Inc., (OTC:FTRK) ("Better For You Wellness" or the "Company"), an Ohio-based blank check company, is pleased to announce that it has appointed five independent non-executive directors to its Board of Directors including Montel Williams, Leslie Bumgarner, Joseph Watson, David Deming, and Dr. Nicola Finley, MD (the "New Directors"). All five New Directors have been appointed for initial terms of 2 years, and Better For You Wellness, Inc.'s seven member Board of Directors is now composed of a majority of Independent Directors demonstrating the Company's focus on governance and growth plan.

    "The appointment of these five all-star independent directors marks a major milestone for the Company," commented Ian James, Chief Executive Officer and Director of Better For You Wellness. "This diverse group of new Directors brings a vast pool of strategic guidance from many different industries and professional backgrounds, which will lend itself to the Company's aggressive growth plan. Furthermore, the Company's 5:2 majority of non-executive independent directors means that Better For You Wellness, Inc. is one step closer to meeting the listing requirements for up-listing to a national securities exchange such as the NASDAQ or NYSE." 

    Additional information about the New Directors can be found below:

    Montel Williams

    Montel Williams earned his media celebrity status as an Emmy Award winning television personality and radio talk show host. Mr. Williams is also a decorated Naval officer, inspirational speaker, author, wellness entrepreneur and health advocate. Additionally, Mr. Williams was a Founder of Helius Medical Technologies, Inc. (NASDAQ:HSDT), a neurotechnology company that focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Mr. Williams was also the Founder of the Montel Williams MS Foundation, a 501(c)(3) organization devoted to researching Multiple Sclerosis and helping people suffering from Multiple Sclerosis. Mr. Williams enlisted in the United States Marine Corps in 1974. Mr. Williams received a B.S. in Engineering from the United States Naval Academy in 1980, and served in the United States Navy in active duty until 1991, and as a reservist until 1996 when he retired at the rank of Lieutenant Commander. Mr. Williams' awards include two Meritorious Service Medals, two Navy Commendation Medals, the National Defense Service Medal, the Navy Achievement Medal, two Navy Expeditionary Medals, the Armed Forces Expeditionary Medal and two Humanitarian Service Medals.

    Leslie Bumgarner

    With decades of executive-level experience in the financial industry, Leslie Bumgarner is the President and CEO of and Chief Executive Officer of Telhio Credit Union, a $1.3 billion financial cooperative serving Central and Southwest Ohio. Ms. Bumgarner has served as a volunteer with Ronald McDonald House Charities of Central Ohio since 2010 and currently serves as the Vice Chair of the Board of Trustees. Ms. Bumgarner also serves as a member of the Executive Committee of the Hamilton, Ohio Chamber of Commerce and serves as Vice Chair of the Board of Cooperative Business Services, a commercial lending institution. Ms. Bumgarner received a B.S. in Business Administration in 1979 from Ohio State University.

    Joseph Watson

    With decades of executive-level experience as a leader and visionary in the pet industry, Joseph Watson is President and Chief Executive Officer of Petland, Inc., a global pet products retailer with stores in eight countries. Mr. Watson began at Petland as Vice President of Operations in November 2005 and then served as Chief Operating Officer prior to becoming CEO. Since July 2015, Mr. Watson is a member of the Board of Trustees of Shawnee State University and serves as the Chairman of the Board of Trustees of Adena Health System, a medical services provider with four hospitals and six regional clinics in Ohio. Mr. Watson served in the United States Army from 1985 to 1987 and is also a National Guard veteran. Mr. Watson received a B.S. in Communications System Management from Ohio University in 1992, and received a Master's in Business Administration from Ohio University in 1999.

    David Deming


    With decades of senior-level investment banking experience, David Deming serves as Partner and Chief Operating Officer of ID Fund LLC, an investor-directed firm for accredited investors. Mr. Deming formerly served as a director of Sorrento Therapeutics Inc. (NASDAQ:SRNE), a clinical stage and commercial-stage biopharmaceutical company that develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases, and has served on the board of numerous other public and private biotechnology companies, in addition to serving on the Board of Trustees of Hobart and William Smith Colleges for over a decade. Mr. Deming started fis career at J.P. Morgan in 1976 and was a Managing Director in charge of the Global Healthcare Investment Banking Group from 1991 to 2003. Mr. Deming received a B.A. in Economics from Hobart College in 1975.

    Dr. Nicola Finley, MD


    As a board certified internal medicine physician with decades of experience as a practicing physician, Dr. Nicola R. Finley currently serves as Adjunct Faculty in the Health Promotion Sciences Division at the Mel and Enid Zuckerman College of Public Health at the University of Arizona, where she lectures to undergraduate, graduate and medical students, and presents to staff and faculty on the topic of personal wellness. Dr. Finley also serves as an Advisory Board Member of the Global Wellness Summit, an organization that gathers leaders and visionaries in the wellness industry, and serves as an Advisory Council Member at Luma Wealth, a wealth management firm that focuses on advising women and their families. Dr. Finley also serves as a Community Advisory Board Member of Arizona Public Media, a Southern Arizona-based non-profit public media service providing television and radio content including NPR and PBS to the area. Dr. Finley has had her research published in the American Journal of Lifestyle Medicine and Current Sexual Health Reports. Dr. Finley authored Function: A multidimensional view for the International Council on Active Aging®, and wrote the chapter on "Women's Sleep" in Integrative Sleep Medicine published by Weil Integrative Medicine Library. Dr. Finley received a B.A. in Educational Studies from Brown University in 1994, and received a M.D. from the George Washington University School of Medicine in 1998.

    Further to the Company's press release on August 19, 2021, The Company's name change from Fast Track Solutions, Inc. to Better For You Wellness, Inc. (the "Name Change") has become effective in the State of Nevada. The Company is still awaiting notification from FINRA that the Name Change has been processed. The Company is actively exploring and evaluating various business opportunities in the plant-based food, beverage, and consumer packaged goods ("CPG") categories including, but not limited to, mergers, acquisitions, or business combination transactions, after which the Company would cease to be a "shell" or "blank check" company. 

    About Better For You Wellness, Inc.

    Better For You Wellness, Inc., formerly known as Fast Track Solutions, Inc., (OTC:FTRK) is a Columbus, Ohio-based blank-check company that is exploring and evaluating various business opportunities in the plant-based food, beverage, and consumer packaged goods ("CPG") categories including, but not limited to, mergers, acquisitions, or business combination transactions, after which the Company would cease to be a "shell" or "blank check" company. Learn more at https://betterforyouwellness.com/.

    Forward-Looking Statements

    This press release may contain forward-looking statements that involve risks and uncertainties. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology including "could," "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" and the negative of these terms or other comparable terminology. While these forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgment regarding the direction of our business, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggested in this report. Except as required by applicable law, we do not intend to update any of the forward-looking statements so as to conform these statements to actual results. Investors should refer to the risks disclosed in the Company's reports filed with SEC (https://www.sec.gov/).

    Attachment

    • Better For You Wellness, Inc.'s New Board Members-Max-Quality


    Fast Track Solutions Inc.
    [email protected]
    
    Get the next $HSDT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HSDT
    $SRNE

    CompanyDatePrice TargetRatingAnalyst
    Sorrento Therapeutics Inc.
    $SRNE
    11/2/2022$5.00Overweight
    Cantor Fitzgerald
    Helius Medical Technologies Inc.
    $HSDT
    11/15/2021Outperform → Market Perform
    Noble Capital Markets
    Sorrento Therapeutics Inc.
    $SRNE
    8/9/2021$30.00 → $26.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $HSDT
    $SRNE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Andreeff Dane bought $8,229 worth of shares (1,284 units at $6.41) (SEC Form 4) (Amendment)

      4/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

      2/15/24 4:06:00 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Andreeff Dane bought $40,475 worth of shares (5,000 units at $8.10) (SEC Form 4)

      4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

      12/15/23 7:00:42 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Andreeff Dane bought $25,675 worth of shares (4,006 units at $6.41) (SEC Form 4)

      4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

      12/4/23 8:30:12 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HSDT
    $SRNE
    Financials

    Live finance-specific insights

    See more
    • Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025

      US Bankruptcy Court for the Southern District of Texas issued an order to extend the lock-up period on the Scilex Dividend Stock, previously distributed by Sorrento, to April 14, 2025.Accordingly, any shares of the Dividend Stock (including any such shares held by brokerage firms) may not be sold, transferred or otherwise disposed of.Scilex's transfer agent, Continental Stock Transfer & Trust Company, has been notified of the lock-up extension to April 14, 2025. PALO ALTO, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain manag

      1/31/25 9:00:00 AM ET
      $SCLX
      $SRNE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
    • Helius Medical Technologies, Inc. Provides Updates on Efforts to Achieve Fair Market Access for its Portable Neuromodulation Stimulator (PoNS®) Device

      NEWTOWN, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today provided updates on its efforts to achieve fair market access for its Portable Neuromodulation Stimulator (PoNS) device and announced plans to host a business update call today at 9:00am ET.   "We disagree with the proposed pricing for the PoNS Mouthpiece and are disappointed CMS has once again mapped the Controller pricing to a code for fundamentally different technology," said Dane Andreeff, Helius' President and Chief Executive Officer. "I

      11/18/24 8:01:00 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Helius Medical Technologies, Inc. to Release Second Quarter 2024 Financial Results on August 12, 2024

      NEWTOWN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its second quarter 2024 financial results on Monday, August 12, 2024, after the market closes. Dane C. Andreeff, President and Chief Executive Officer, and Jeffrey S. Mathiesen, Chief Financial Officer will host a conference call to discuss the results and provide an expanded business update regarding Helius' progress and plans surrounding the U.S. commercialization of PoNS® as follows: Date:Monday, Augus

      8/6/24 4:36:06 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HSDT
    $SRNE
    Leadership Updates

    Live Leadership Updates

    See more
    • Helius to Spotlight Study Confirming Improved Long-Term Outcomes from Adherence to PoNS Therapy® at CMSC Annual Meeting

      NEWTOWN, Pa., May 20, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced it will highlight the results of a new study confirming the therapeutic regimen and sustained efficacy of its Portable Neuromodulation Stimulator (PoNS®) device for people with multiple sclerosis (MS) at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting. The event runs from May 28-31 at the Phoenix Convention Center in Phoenix. Deborah Backus, PT, Ph.D., FACRM – Vice President of Research and Innovation at Atlanta's Shepherd Center, one of six sit

      5/20/25 7:00:00 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Scilex Holding Company, a Sorrento Company, announces that the Honorable Tommy G. Thompson has joined the Scilex Board of Directors

      PALO ALTO, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced today the appointment of the Honorable Tommy G. Thompson, former Secretary of the United States Department of Health and Human Services ("HHS") and former Governor of Wisconsin, to its Board of Directors. Governor Thompson's appointment is effective immediately. Governor Thompson currently serves as the Chief Executive Officer of Thomp

      7/5/22 2:04:42 PM ET
      $SRNE
      $VCKA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Sorrento Therapeutics, Inc. announces the appointment of the Honorable Tommy G. Thompson, as Covid-19 Special Consultant to Chairman and CEO Henry Ji

      SAN DIEGO, June 24, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), a commercial and clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies and diagnostics, announced today the appointment of the Honorable Tommy G. Thompson, former Secretary of the United States Department of Health and Human Services ("HHS") and former Governor of Wisconsin, as Covid-19 special consultant to Sorrento's Chairman and CEO Henry Ji. Governor Thompson's appointment is effective immediately. Most recently, Thompson served as the President of the University of Wisconsin System from July 2020 through March 2022, one of the largest

      6/24/22 3:38:28 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $HSDT
    $SRNE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Helius Medical Technologies Announces Pricing of $9.1 Million Public Offering

      NEWTOWN, Pa., June 04, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced the pricing of its public offering of an aggregate of 2,768,600 shares of its Class A common stock (or common stock equivalents), and warrants to purchase up to 2,768,600 shares of common stock, at a combined public offering price of $3.27 per share and accompanying warrants. Each Warrant will expire two and one-half (2.5) years from the issuance, will be immediately exercisable upon issuance at an initial exercise price of $7.3575 pe

      6/4/25 9:12:02 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Helius Medical Technologies, Inc. Compliant with Nasdaq Bid Price Rule Listing Criteria

      NEWTOWN, Pa., June 04, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that on June 3, 2025, Helius received formal notice from the Nasdaq Hearings Panel of The Nasdaq Stock Market LLC (the "Panel") indicating that Helius has evidenced full compliance with the minimum bid price requirement set forth Listing Rules 5550(a)(2) (the "Bid Price Rule"). The Panel further reminded the Company that it is also required to regain compliance with the equity requirement in Listing Rule 5550(b)(1) (the "Equity Rule")

      6/4/25 7:00:00 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Helius to Spotlight Study Confirming Improved Long-Term Outcomes from Adherence to PoNS Therapy® at CMSC Annual Meeting

      NEWTOWN, Pa., May 20, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced it will highlight the results of a new study confirming the therapeutic regimen and sustained efficacy of its Portable Neuromodulation Stimulator (PoNS®) device for people with multiple sclerosis (MS) at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting. The event runs from May 28-31 at the Phoenix Convention Center in Phoenix. Deborah Backus, PT, Ph.D., FACRM – Vice President of Research and Innovation at Atlanta's Shepherd Center, one of six sit

      5/20/25 7:00:00 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HSDT
    $SRNE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $HSDT
    $SRNE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SEC Form 4 filed by CFO and Treasurer Mathiesen Jeffrey S

      4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

      1/8/25 4:10:32 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Director Perkins Sherrie L

      4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

      1/8/25 4:10:39 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Favit-Van Pelt Antonella R.

      4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

      1/8/25 4:10:36 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cantor Fitzgerald initiated coverage on Sorrento Therapeutics with a new price target

      Cantor Fitzgerald initiated coverage of Sorrento Therapeutics with a rating of Overweight and set a new price target of $5.00

      11/2/22 6:29:52 AM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Helius Medical Tech downgraded by Noble Capital Markets

      Noble Capital Markets downgraded Helius Medical Tech from Outperform to Market Perform

      11/15/21 10:55:44 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • HC Wainwright & Co. reiterated coverage on Sorrento Therapeutics with a new price target

      HC Wainwright & Co. reiterated coverage of Sorrento Therapeutics with a rating of Buy and set a new price target of $26.00 from $30.00 previously

      8/9/21 6:25:18 AM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $HSDT
    $SRNE
    SEC Filings

    See more
    • SEC Form 424B4 filed by Helius Medical Technologies Inc.

      424B4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Filer)

      6/5/25 8:00:49 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form EFFECT filed by Helius Medical Technologies Inc.

      EFFECT - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Filer)

      6/5/25 12:15:33 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Helius Medical Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Filer)

      6/4/25 8:31:47 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HSDT
    $SRNE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Helius Medical Technologies Inc.

      SC 13G/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)

      11/8/24 5:12:24 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by Helius Medical Technologies Inc.

      SC 13G - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)

      5/14/24 4:15:39 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Helius Medical Technologies Inc. (Amendment)

      SC 13G/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)

      2/13/24 7:09:07 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care